Chemotherapy of Leishmaniasis and human trypanosomiasis: Current state and new developments;Chemotherapie der Leishmaniose und humanen trypanosomose: Status und neue entwicklungen

Pharmazie in Unserer Zeit

Volumn 28, Issue 4, 1999, Pages 177-185

  Kayser, Oliver ^a,b   Croft, Simon L ^c,d,e   Kolodziej, Herbert ^a,b,e  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c DURHAM UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 5' [(4 AMINO 2 BUTENYL)METHYLAMINO] 5' DEOXYADENOSINE; ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ARSANILIC ACID; CPG 40215; EFLORNITHINE; ILMOFOSINE; ITRACONAZOLE; KETOCONAZOLE; LICOCHALCONE A; MEGLUMINE ANTIMONATE; MELARSOPROL; MILTEFOSINE; N,N' BIS(3 BENZYLAMINOPROPYL) 1,7 HEPTANEDIAMINE; NIFURTIMOX; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; RANITIDINE; SITAMAQUINE; STIBOGLUCONATE SODIUM; SURAMIN; TRYPARSAMIDE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; CHAGAS DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIASIS; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; TRYPANOSOMIASIS;

EID: 0032787838     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/pauz.19990280404     Document Type: Review

References (31)

1. WHO: Report on the Joint WHO/ MZCP/HPI Workshop on the Epidemiology, Diagnosis and Control of Leishmaniasis in the Mediterranean Area, Athen 1993.
2. Van Voorhis, W. C.: Therapy and prophylaxis of systematic protozoan infections, Drugs 40 (1990), 176-202.
3. Harms, G.; Bienzle, U.: Leishmaniosen. In: Lang, W. (Hrsg.): Tropenmedizin in Klinik und Praxis. Georg Thieme Verlag, Stuttgart (1993), 37-53.
4. Salfelder, K.: Leishmaniasis. In: Salfelder, K.; Sauerteig, E.: Protozoan Infections in Man. Schwabenverlag, Ostfildern (1988), 49-64.
5. Olliaro, P.L.; Bryceson, A.D. M.: Practical Progress and New Drugs for Changing Patterns of Leishmaniasis, Parasitology Today 9 (1993), 323-328.
6. Navin, T. R.; Arana, B. A.; Arana, F. E.; Berman, J. D.; Chajon, J. F.: Placebo Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazol for Treating Cutaneous Leishmaniasis in Guatemala, Journal of Infectious Diseases 165 (1992), 528-534.
7. Berman, J. D.: Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies, Reviews in Infectious Diseases, 1988, 560-586.
8. Roberts, W.L.; Berman, J. D.; Rainey, P. M.: In Vitro Antileishmanial Properties of tri- and pentavalent antimonial preparations, Antimicrobial Agents and Chemotherapy 39 (1995), 1234-1239.
9. Croft, S. L.; Urbina, J. A.; Brun, R.: Chemotherapy of Human Leishmaniasis and Trypanosomiasis. In: Hide, G.; Mottram, J. C.; Cooms, G. H.; Holmes P. H. (Eds.): Leishaniasis and Trypanosomiasis: biology and control. CAB International, Oxford (1997), 245-257.
10. El-On, J.; Halvey, S.; Grunwald, M. H.; Weinraueh, L.: Tropical Treatment of Old World Cutaneous Leishmaniasis caused Leishmania major - a Double Blind Study, Journal of the American Academy of Dermatology 27 (1992), 227-231.
11. Martinez, S.; Marr, J. J.: Allopurinol in the Treatment of American Cutaneous Leishmaniasis, New England Journal of Medicine 326 (1992), 741-744.
12. Sundar, S.; Rosenkaimer, F.; Murray, H. W.: Succesful Treatment of Refractory Visceral Leishmaniasis in India Using Antimony and plus Interferon-γ, Journal of Infectious Diseases 17C (1994), 659-662.
13. Baumann, R. J.; McCann, P. P.; Biconti, A. J.: Suppression of Leishmania donovani by Oral Administration of a Bis(benzyl)polyamine analog, Antimicrobial Agents and Chemotherapy 35 (1991), 1403-1407.
14. Chen, M.; Christensen, S. B.; Theander, T. G.; Kharazami, A.: Antileishmanial Activity of Licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani, Antimicrobial Agents and Chemotherapy 38 (1994), 1339-1344.
15. WHO: Chagas Disease: Central American Initiative launched, TDR News (1998), 6.
16. Boveris, A.; Sies, H.; Martino, E. E.; Docampo, R.; Turrens, J.F.; Stoppani, A. O. M.: Defiecent metabolic utilization of hydrogen peroxide in Trypanosoma cruzi, Biochemistry Journal 188 (1980), 643-648.
17. Rassi, A.; Luquetti, A. O.: Therapy of Chagas's Diseases. In: Wendel, S.; Brener, Z.; Camargo, M. E.; Rassi, A. (Eds.): Chagas Diseases (American Trypanosomiasis): its impact on Transfusion and Clinical Medicine. ISBT BRAZIL'92, Sao Paulo, Brazil (1992), 237-247.
18. De Castro, S. L.: The Challenge of Chagas' Diseases Chemotherapy: An Update of Drugs Assayed Against Trypanosoma cruzi, Acta Tropica 53 (1993), 83-98.
19. Gianelli, A.: Alopurinol en la Enfermedad de Chagas Cronica. Reuniao Anual de Pesquisa Aplicada en Doenca de Chagas 10 (1994), 89.
20. Brener, Z.; Candado, J. R.; Gavao, L. M.; da Luz, Z. M. P.; Filardi, L. D. S.; Pereira, M. E. S.; Santos, L. M. S.; Cancado, C. D.: An Experimental and Clinical Assay with Ketoconazole in the Treatment of Chagas' Disease, Memorias do Instituto Oswaldo Cruz 88 (1993), 149-153.
21. Croft, S. L., persönliche Meinung.
22. Croft, S. L., unveröffentlicht.
23. Albengres, E.; Le Louet, H.; Tillement, J. P.: Systematic antifungal agents. Drug interactions of clinical significance, Drug Safety 18 (1998), 83-97.
24. Molyneux, D. H.: Vectors. In: Cox, F. E. G. (Eds.) Modern Parasitology. Blackwell Scientific Publications, Oxford, London, Edinburgh, Boston, Melbourne, Paris, Berlin, Vienna (1993), 53-74.
25. Vercruysse, J.; Taraschewski, H.; Voigt, W. P.: Main clinical and pathological signs of parasitic infections in domestic animals. In: Mehlhorn, H. (Eds.) Parasitology in focus, Facts and Trends. Springer Verlag, Berlin, Heidelberg, New York, London, Paris, Tokyo (1988), 477-532.
26. Pepin, J.; Milford, F.: The Treatment of Human African Trypanosomiasis, Advances in Parasitology 33 (1994), 1-47.
27. Iten, M.; Matovu, E.; Brun, R.; Kaminsky, R.: Innate Lack of Susceptibility of Ugandan T. b. rhodesiens to DL-α-Difluoroethylornithin (DFMO), Tropical Medicine and Parasitology 46 (1995), 190-194.
28. Item, M.; Kaminsky, R.: Alterations in ornithine decarboxylase characteristics account for tolerance in T. brucei rhodesiense to DFMO, Antimicrobial Agents and Chemotherapy 41 (1997), 1922-1925.
29. Jennings, F. W.: Combination chemotherapy of CNS Trypanosomiasis, Acta Tropica 54 (1993), 205-213.
30. Bitonti, A. J.; Byers, T. L.; Casara, P. J.; Bacchi, C. J.; Clarkson, A. B.; McCann, P.P.; Sjoerdsma, A.: Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-Adenosylmethione decarboxalase, Antimicrobial Agents and Chemotherapy 34 (1990), 1485-1490.
31. Abdi, Y. A.; Gustafson, L. L.; Ericsson, O.; Hellgren, U. (Eds.) Handbook of Drugs for Tropical Parasitic Infections. Taylor and Francis, Oxford, London (1995).